Pancreatic Cancer Research

Clinical trialPhase 1Completed

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
1 September 2019
Ended
8 August 2025
Enrollment
25 participants
Sites
1
Primary outcomes
Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (RAP-1); Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (PD endpoints); Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (cmax); Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (Tmax); Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (half life)
Sponsor type
Industry
Results posted
No
Last update
2 September 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies. PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed. Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.